Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR) have produced impressive minimal residual disease–negative (MRD-negative) complete remission (CR) rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the factors asso...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Hay, Kevin A., Gauthier, Jordan, Hirayama, Alexandre V., Voutsinas, Jenna M., Wu, Qian, Li, Daniel, Gooley, Ted A., Cherian, Sindhu, Chen, Xueyan, Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Steinmetz, Rachel N., Schoch, Gary, Chapuis, Aude G., Till, Brian G., Kiem, Hans-Peter, Ramos, Jorge D., Shadman, Mazyar, Cassaday, Ryan D., Acharya, Utkarsh H., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Immunobiology and Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6460418/
https://ncbi.nlm.nih.gov/pubmed/30728140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-11-883710
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars